表觀遺傳學相關藥物和診斷技術市場（按類型分類）

Epigenetics Drugs and Diagnostic Technologies Market, by Type

出版日期: 2026年04月27日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，表觀遺傳學相關藥物和診斷技術市場規模將達到 188.1 億美元，到 2033 年將達到 635.8 億美元。預計 2026 年至 2033 年的複合年成長率將達到 19.0%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	188.1億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	19.00%	2033年市場規模預測：	635.8億美元

基因突變通常會擾亂正常的基因表現過程，導致疾病的發生。然而，近期發現的表觀遺傳學改變已展現出顯著影響腫瘤對治療方案反應的潛力。此類表觀遺傳改變已被證實具有動態性，因此也是可逆的。這種可逆性為利用表觀遺傳療法改善化療反應提供了廣闊的前景。潛在的表觀遺傳藥物候選物可以透過「藥物重定位」或「藥物再利用」這一過程找到，這是一種從已批准的藥物中發現新潛在目標的有效策略。目前，一些新的表觀遺傳藥物候選物已在臨床前試驗中被發現，另一些則正在臨床試驗中進行檢驗，使其具備了重定位的條件。表觀遺傳藥物再利用的主要重點是開發僅針對單一適應症的藥物，為患者提供低成本的治療選擇，同時引入一種新的精準醫療方法來最佳化療效並降低毒性。表觀遺傳學藥物已被廣泛用於治療感染疾病、糖尿病視網膜病變、心臟功能障礙、思覺失調症以及包括創傷後壓力症候群（PTSD）在內的精神疾病。它們分為四類：Hydroxamates（伏立諾他、貝利諾他、Panobinostat）、Benzamides（恩替諾他、噻達米德）、環肽類（羅米地辛）和脂肪酸類。

市場動態

預計主要市場參與者不斷推出新產品以及併購將推動全球表觀遺傳藥物和診斷技術市場的成長。例如，2021年11月4日，總部位於美國的臨床階段生物製藥公司Epizyme, Inc.宣布，其First-in-Class的口服SETD2抑制劑EZM0414已獲得美國食品藥物管理局（FDA）的「快速通道」資格，用於臨床實驗復發或難治性瀰漫性大B細胞淋巴瘤（DLBCL）成人患者。該公司還啟動了一項I/Ib期臨床試驗，以評估EZM0414的安全性並確定最佳劑量。

本次考試的主要特點：

這項研究揭示了各個細分市場的潛在成長機會，並為該市場說明了一個有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數介紹了全球表觀遺傳藥物和診斷市場中主要公司的概況：公司概況、產品系列、主要亮點、財務表現和策略。
本研究涵蓋的主要公司包括 Regenacy Pharmaceuticals, Inc.、Astex Pharmaceuticals、4SC AG、CellCentric Ltd.、Celleron Therapeutics Ltd.、Bristol-Myers Squibb Company、Oryzon Genomics SA、ChromaMedicine, Inc.、Epizyme,Gen Inc. 和 Epizyme, Inc.
本報告提供的見解將有助於各公司的行銷負責人和經營團隊就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份《全球表觀遺傳學藥物和診斷市場》報告的目標受眾是該行業的眾多相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用分析全球表觀遺傳藥物和診斷市場中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第6章競爭情勢

Regenacy Pharmaceuticals, Inc.
Astex Pharmaceuticals
4SC AG
CellCentric Ltd
Celleron Therapeutics Ltd.
Bristol-Myers Squibb Company
Oryzon Genomics SA
ChromaMedicine, Inc.
Epizyme, Inc.
EpiGentek Group Inc.

第7章

調查方法
關於本公司

簡介目錄

Product Code: CMI4026

Epigenetics Drugs and Diagnostic Technologies Market is estimated to be valued at USD 18.81 Bn in 2026 and is expected to reach USD 63.58 Bn by 2033, growing at a compound annual growth rate (CAGR) of 19.0% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 18.81 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	19.00%	2033 Value Projection:	USD 63.58 Bn

Gene mutations often result in the disruption of normal processing of genes and leads to the development of diseases. However, recently discovered epigenetic alterations have shown the potential to greatly influence tumoral response to therapy regimens. Such epigenetic alterations have proven to be dynamic, and thus could be restored. Due to their reversible nature, the promising opportunity to improve chemotherapy response using epigenetic therapy has arisen. Potential epidrug candidates can be found through a process known as drug repositioning or repurposing, a promising strategy for the discovery of novel potential targets in already approved drugs. At present, novel epidrug candidates have been identified in preclinical studies and some others are currently being tested in clinical trials, ready to be repositioned. The main focus of epidrug repurposing is the development of agents with one indication only, while giving patients lower cost therapies and a novel precision medical approach to optimize treatment efficacy and reduce toxicity. Epigenetic drugs are commonly used in the treatment of infections, cancer, diabetic retinopathy, cardiac dysfunction, schizophrenia, and mental problems including posttraumatic stress disorder. They are categorized into four classes: hydroxamates (vorinostat, belinostat, panobinostat), benzamides (entinostat, chidamide), cyclic peptides (romidepsin), and aliphatic acids.

Market Dynamics

Increasing new product launches, and mergers and acquisitions by key market players is expected to drive the global epigenetics drugs & diagnostic technologies market growth. For instance, on November 4, 2021, Epizyme, Inc., a U.S. based clinical-stage biopharmaceutical company developing and delivering novel epigenetic therapies, announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to EZM0414, the company's novel, first-in-class, oral SETD2 inhibitor, as an investigational agent for the treatment of adult patients with relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL). The company has also initiated a Phase 1/1b study to evaluate safety and determine the optimal dose of EZM0414.

Key features of the study:

It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global epigenetics drugs & diagnostic technologies market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
The key companies covered as a part of this study include Regenacy Pharmaceuticals, Inc., Astex Pharmaceuticals, 4SC AG, CellCentric Ltd., Celleron Therapeutics Ltd., Bristol-Myers Squibb Company, Oryzon Genomics S.A., ChromaMedicine, Inc., Epizyme, Inc., and EpiGentek Group Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global epigenetics drugs & diagnostic technologies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global epigenetics drugs & diagnostic technologies market

Detailed Segmentation:

Global Epigenetics Drugs and Diagnostic Technologies Market, By Type (Revenue, USD Bn, 2021 - 2033)
Epigenetic Drugs
- DNMT Inhibitors
  - Azacitidine
  - Decitabine
- HDAC Inhibitors
  - Vorinostat
  - Romidepsin
- Others
Epigenetics Diagnostic Technologies
- DNAMethylation
- CHIP Technology
Global Epigenetics Drugs and Diagnostic Technologies Market, By Region (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC
- Israel
- Rest of Middle East
Africa
- South Africa
- Central Africa
- North Africa
Company Profiles
Regenacy Pharmaceuticals, Inc.
Astex Pharmaceuticals
4SC AG
CellCentric Ltd.
Celleron Therapeutics Ltd.
Bristol-Myers Squibb Company
Oryzon Genomics S.A.
ChromaMedicine, Inc.
Epizyme, Inc.
EpiGentek Group Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Epigenetic Drugs & Diagnostic Technologies Market, By Type, 2021-2033, (US$ Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Epigenetic Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
  - DNMT Inhibitors
  - HDAC Inhibitors
  - Others
Epigenetics Diagnostic Technologies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
  - DNAMethylation
  - CHIP Technology

5. Global Epigenetic Drugs & Diagnostic Technologies Market, By Region, 2021-2033, (US$ Billion)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2021-2033, (US$ Billion)
  - North Africa
  - Central Africa
  - South Africa

6. Competitive Landscape

Regenacy Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Astex Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
4SC AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
CellCentric Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Celleron Therapeutics Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Oryzon Genomics S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
ChromaMedicine, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Epizyme, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
EpiGentek Group Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies